Authors | Years of patient inclusion | Type of study | Clinical stage | N | SSC/AC proportion % | OS | P-value |
---|---|---|---|---|---|---|---|
Galic et al. (2012) | 1988–2005 | Retrospective multicenter | IIB-IVA | 10,217 | 84.2/10.8/5.0a | 32.5/17.9/29.2 | 0.014b |
Katanyoo et al. (2012) | 1995–2008 | Retrospective | IIB-IVA | 423 | 66.7/33.3 | 61.7/59.9 | 0.191 |
Intaraphet et al. (2013) | 1995–2011 | Retrospective | I-IV | 1978 | 82.5/17.5 | 60/54.7 | < 0.001 |
Rose et al. 2014 | Retrospective 5 clinical trials | IB2-IVA | 1671 | 89.1/10.9c | ––––––– | 0.459 | |
Chen et al. (2014) | 1995–2009 | Retrospective | IIB-IVA | 229 | 84.7/15.3c | 58.1/41.3 | 0.090 |
Yun Lee et al. (2015) | 1993–2012 | Retrospective | 3156 | 85.0/15.0 | –––––––- | 0.003 | |
Zhou et al. (2017) | 1988–2013 | Retrospective multicenter | I-IV | 8751 | 86/10.6/3.4a | 51.1/40.3 | < 0.001 |
Yokoi et al. (2017) | 1993–2014 | Retrospective | IIB-IVA | 249 | 90.4/9.6 | 58.6/26.7 | 0.004 |
Seamon et a (2017) | 1999–2012 | Retrospective 3 clinical trials treated whit chemotherapy doublets | IVBξ | 781 | 77/23 | 10.3/15.1 | 0.093 |
Cheng Yin et al. (2018) | 2004–2016 | Retrospective Single center | IB2-IVA | 181 | 83.4/16.5 | 78.6/46.0 | < 0.001 |
Hu et al. (2018) | 2011–2014 | Retrospective | IB-IVA | 815 | 91.2/8.7 | 85.2/74.4 | 0.005 |
Jonska-Gmyrek et al. (2019) | 2004–2012 | Retrospective | IIB IIIA-IIIB | 161 | 67.7/32.3 | 81.7/62.8 73.1/33.6 | 0.03 0.005 |
Current Study | 2005–2014 | Retrospective Single center | IB2-IVA | 1291 | 1154/137 | 74.3/60.0 | 0.004 |